3 stories
Amazon Pharmacy has become an increasingly visible distribution channel for branded GLP-1 drugs. The 2026 expansion to oral Wegovy with both insurance and cash-pay options signaled a broader retail push to capture surging oral GLP-1 demand.
Stories on this site cover Amazon Pharmacy's GLP-1 channel expansions, insurance integration moves, and the competitive frame against LillyDirect, NovoCare, and the telehealth platforms. The push has also highlighted the broader question of where retail-pharmacy economics on peptide drugs end up.
Stories here cover the distribution moves and the pricing impact. See #pricing and #telehealth for related threads.
Telehealth rival Hims & Hers Health shares slid 6% April 21-22 after Amazon's One Medical launched a comprehensive GLP-1 weight management program offering Wegovy and Foundayo starting at $25/month with insurance or $149/month cash-pay for oral options. The move positions Amazon against established telehealth obesity care providers (Hims, Ro, LifeMD, Noom) as the compounded-GLP-1 era winds down.
Amazon One Medical launched a nationwide GLP-1 Management Program offering Wegovy, Zepbound, and Lilly's Foundayo starting at $25/month with insurance, plus $149/month cash-pay for oral drugs and $299/month for injectables. Same-day delivery in nearly 3,000 cities, expanding to 4,500 by year-end. Shares of Eli Lilly, Novo Nordisk, and Hims & Hers fell on the news.
Amazon Pharmacy expanded access to the new oral Wegovy pill with both insurance and cash-pay options, signaling a broader retail push to capitalize on surging oral GLP-1 demand.